Carolyn S Kaufman1, Jill K Morris2,3, Eric D Vidoni2,3, Jeffrey M Burns2,3, Sandra A Billinger1,2,4. 1. Departments of Molecular and Integrative Physiology. 2. Neurology. 3. University of Kansas Alzheimer's Disease Center, Fairway, KS. 4. Physical Therapy and Rehabilitation Science, University of Kansas Medical Center.
Abstract
BACKGROUND: The strongest genetic risk factor for late-onset Alzheimer disease (AD), Apolipoprotein E4 (APOE4), increases cardiovascular disease risk and may also act synergistically with vascular risk factors to contribute to AD pathogenesis. Here, we assess the interaction between APOE4 and vascular risk on cerebrovascular dysfunction and brain pathology. METHODS: This is an observational study of cognitively normal older adults, which included positron emission tomography imaging and vascular risk factors. We measured beat-to-beat blood pressure and middle cerebral artery velocity at rest and during moderate-intensity exercise. Cerebrovascular measures included cerebrovascular conductance index and the cerebrovascular response to exercise. RESULTS: There was a significant interaction between resting cerebrovascular conductance index and APOE4 carrier status on β-amyloid deposition (P=0.026), with poor conductance in the cerebrovasculature associated with elevated β-amyloid for the APOE4 carriers only. There was a significant interaction between non-high-density lipoprotein cholesterol and APOE4 carrier status (P=0.014), with elevated non-high-density lipoprotein cholesterol predicting a blunted cerebrovascular response to exercise in APOE4 carriers and the opposite relationship in noncarriers. CONCLUSIONS: Both cerebral and peripheral vascular risk factors are preferentially associated with brain pathology in APOE4 carriers. These findings provide insight into pathogenic vascular risk mechanisms and target strategies to potentially delay AD onset.
BACKGROUND: The strongest genetic risk factor for late-onset Alzheimer disease (AD), Apolipoprotein E4 (APOE4), increases cardiovascular disease risk and may also act synergistically with vascular risk factors to contribute to AD pathogenesis. Here, we assess the interaction between APOE4 and vascular risk on cerebrovascular dysfunction and brain pathology. METHODS: This is an observational study of cognitively normal older adults, which included positron emission tomography imaging and vascular risk factors. We measured beat-to-beat blood pressure and middle cerebral artery velocity at rest and during moderate-intensity exercise. Cerebrovascular measures included cerebrovascular conductance index and the cerebrovascular response to exercise. RESULTS: There was a significant interaction between resting cerebrovascular conductance index and APOE4 carrier status on β-amyloid deposition (P=0.026), with poor conductance in the cerebrovasculature associated with elevated β-amyloid for the APOE4 carriers only. There was a significant interaction between non-high-density lipoprotein cholesterol and APOE4 carrier status (P=0.014), with elevated non-high-density lipoprotein cholesterol predicting a blunted cerebrovascular response to exercise in APOE4 carriers and the opposite relationship in noncarriers. CONCLUSIONS: Both cerebral and peripheral vascular risk factors are preferentially associated with brain pathology in APOE4 carriers. These findings provide insight into pathogenic vascular risk mechanisms and target strategies to potentially delay AD onset.
Authors: David Zade; Alexa Beiser; Regina McGlinchey; Rhoda Au; Sudha Seshadri; Carole Palumbo; Philip A Wolf; Charles Decarli; William Milberg Journal: J Stroke Cerebrovasc Dis Date: 2010-05-14 Impact factor: 2.136
Authors: Salim S Virani; Lynne Steinberg; Tyler Murray; Smita Negi; Vijay Nambi; LeChauncy D Woodard; Biykem Bozkurt; Laura A Petersen; Christie M Ballantyne Journal: Am J Med Date: 2011-09 Impact factor: 4.965
Authors: Emanuele Di Angelantonio; Nadeem Sarwar; Philip Perry; Stephen Kaptoge; Kausik K Ray; Alexander Thompson; Angela M Wood; Sarah Lewington; Naveed Sattar; Chris J Packard; Rory Collins; Simon G Thompson; John Danesh Journal: JAMA Date: 2009-11-11 Impact factor: 56.272
Authors: J Carson Smith; Kristy A Nielson; John L Woodard; Michael Seidenberg; Sally Durgerian; Kathleen E Hazlett; Christina M Figueroa; Cassandra C Kandah; Christina D Kay; Monica A Matthews; Stephen M Rao Journal: Front Aging Neurosci Date: 2014-04-23 Impact factor: 5.750
Authors: Lawrence Labrecque; Kevan Rahimaly; Sarah Imhoff; Myriam Paquette; Olivier Le Blanc; Simon Malenfant; Audrey Drapeau; Jonathan D Smirl; Damian M Bailey; Patrice Brassard Journal: Physiol Rep Date: 2019-01